News
Sanofi partners J&J on E. coli vaccine

Sanofi partners J&J on E. coli vaccine

Sanofi is paying $175 million upfront to claim a share of an experimental vaccine developed by Johnson & Johnson’s pharma unit Janssen that aims to tackle a major caus

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D

Partner Content